A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1133 participants.

Also called NCT06778967

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,133 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06778967
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06778967. Randomized; no masking; primary purpose treatment. Start 2025-02-13 (actual); primary completion 2026-09-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
Acronym
Optimum 2
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
GZR18
Intervention (Drug)
semaglutide
Lead sponsor
Gan & Lee Pharmaceuticals. (class: industry)

Record details

Record id
cardio:ct-nct06778967
Content hash
337c1631d380b7312a524723ccfcd234a8ff67c65d9eb95f76ddebaf5502a76f